L. K. Borysiewicz

TL;DR: Examination of the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 found vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV.

TL;DR: This is the first demonstration that virus-specific CTLs infiltrate the virus-associated tumor, where they may play an important role in restricting disease progression.

TL;DR: Functionally, CD8highCD57+ lymphocytes proliferated strongly to HCMV-, but not HSV-, VZV-, or influenza-infected fibroblasts in an MHC-unrestricted manner in vitro, including preferential augmentation of particular in vivo oligoclonally expanded subpopulations.

TL;DR: The construction and characterisation of a recombinant vaccinia virus designed to express modified forms of the E6 and E7 proteins from HPV16 and HPV18, the viruses most commonly associated with cervical cancer are described.

TL;DR: A tetramer consisting of HLA-A*0201 and the best studied HPV CTL peptide epitope, HPV 16 E711-20, provided a powerful tool to isolate polyclonal and clonal peptide-specific CTLs from an established HPV 16E7,11-21-20- specific CTL line and may be useful for selecting rare high-affinity HPV-specificCTLs for the immunotherapy of CaCx.